The management of locally advanced breast cancer. by Rubens, R. D.
Br. J. Cancer (1992), 65, 145 147
© Macmillan Press
GUEST EDITORIAL
The management of locally advanced breast cancer
R.D. Rubens
ICRF Department of Clinical Oncology, UMDS, Guy's Hospital, London SE] 9RT, UK.
Locally advanced breast cancer carries a high mortality. In a
literature survey covering nearly 2,000 patients, the survival
at 5 years was only 20% (Rubens, 1978). This stage of the
disease usually reflects delay in presentation, although occa-
sionally it takes a rapidly fulminating or 'inflammatory'
form. With increasing public awareness of breast cancer and
its treatment, we may expect the incidence of locally
advanced disease steadily to diminish. For the time being, it
accounts for about 15% of new cases of breast cancer in the
UK, estimated to affect some 3,500 patients each year, while
in developing countries the majority of patients present at
this stage.
Locally advanced disease is characterised by the presence
of one or more of the following features: infiltration of
overlying skin, satellite skin nodules, extensive peau d'orange,
attachment to deep structures, tethering or fixation of axil-
lary nodes, involvement of supraclavicular nodes. It corres-
ponds approximately to stage III of the TNM classification
which encompasses T3,4, any N, MO or any T, N2,3, MO
tumours. This includes some operable tumours, namely T3a,
N0,1, MO, which are in this category solely because of the
large size of the primary tumour. The other categories in
stage III, T3b,4, N0,1, MO or TO-4, N2,3, MO, are generally
considered inoperable and usually treated by radiotherapy.
Inoperable stage III tumours have a significantly worse prog-
nosis than operable disease (Stewart et al., 1982).
Radiotherapy for primary locally advanced breast cancer is
to the whole breast, chest wall and the ipsilateral axillary,
supraclavicular, infraclavicular and internal mammary nodes.
Dose and schedule may vary from centre to centre, but not
the basic principles. For example, the breast and chest wall
may be treated tangentially and the draining lymph nodes
irradiated in continuity by adjacent semi-opposed fields.
Doses of up to 50 Gy are used with boosts approaching
20 Gy to sites of initially palpable disease. Local control is
directly related to the radiation dose and inversely to the
tumour volume (Arriagada et al., 1985). In operable breast
cancer, involvement of the highest axillary lymph node, the
'apex node', is associated with a poor prognosis after mastec-
tomy (van Dongen, 1977). In centres where apex node biopsy
is performed in the staging of breast cancer, radiotherapy
rather than surgery is the preferred treatment when the result
is positive.
Several studies on prognostic factors in Stage III disease
have been reported (Langlands et al., 1976; Rubens et al.,
1977; Zucali et al., 1976). For survival, favourable factors
include a long duration of symptoms (>6 months) before
presentation, deep fixation of the primary tumour, a good
response to primary radiotherapy and the rendering of init-
ially inoperable disease suitable for mastectomy. Unfavour-
able factors are the early postmenopausal years (1-5 years
since last menstrual period), a short duration of symptoms
before presentation (<6 months), diffuse primary tumours
and inflammatory carcinoma. In inoperable locally advanced
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disease, the size of the primary tumour and the presence of
skin involvement appear to be neutral factors for survival,
but have implications for local control. Using these covar-
iates in a multivariate analysis and weighting them appro-
priately, it is possible to define groups of patients with
significantly differing prognoses (Rubens et al., 1977). This
emphasises the importance of considering these variables in
the analysis of clinical trials in locally advanced breast
cancer.
In Stage III disease, the high incidence of subsequent
distant metastases, reaching almost 70% in one series
(Rubens et al., 1977), accounts for the poor survival of
patients treated by radiotherapy alone. This has led to the
study of systemic treatment for its primary management.
Two early studies showed that chemotherapy with doxoru-
bicin and vincristine before radiotherapy for locally advanced
breast tumours gave a response frequency of about 70% and
historical comparisons suggested that survival might be
'improved (De Lena et al., 1978; Rubens et al., 1980). In
Milan, this work was developed further in a randomised
comparison of radiotherapy and radical mastectomy after
primary chemotherapy (Valagussa et al., 1990). There was no
difference in either time to progressive disease or survival.
But both groups received further chemotherapy after local
treatment and this, compared to historical experience, was
observed significantly to improve both end-points. Others
also reported that adjuvant chemotherapy after primary
radiotherapy resulted in significantly better local control and
survival compared to radiotherapy alone in matched historic-
al controls (Bruckman et al., 1979).
Systemic treatment following radiotherapy has now been
tested in two randomised controlled clinical trials. The first
was a three arm trial in which 118 patients were randomised
to either radiotherapy alone, radiotherapy followed by 12
courses of cyclophosphamide, methotrexate and 5-fluoro-
uracil (CMF), or courses of doxorubicin and vincristine
alternating with CMF before and after radiotherapy
(Schaake-Koning et al., 1985). Local control and survival
were not different in the three treatment arms. The second
trial was conducted by the EORTC Breast Cancer Co-opera-
tive Group (Rubens et al., 1989). Its aim was to test the
independent and combined contributions of cytotoxic chemo-
therapy and endocrine therapy to radiotherapy in the pri-
mary treatment of locally advanced disease. In a factorial
design, radiotherapy was the initial treatment for all patients
after which they were randomly allocated to either radiother-
apy alone, radiotherapy + endocrine therapy, radiotherapy +
chemotherapy, or radiotherapy + endocrine therapy +
chemotherapy. Endocrine treatment depended on menstrual
status; premenopausal patients received ovarian irradiation
and prednisolone whilst postmenopausal patients were given
tamoxifen 10 mg bd for 5 years. Those randomised to receive
chemotherapy had 12 cycles of CMF. In 363 evaluable
patients, time to first progression was delayed significantly by
either endocrine treatment or chemotherapy. Unexpectedly,
the effect was due almost entirely to a delay in time to
locoregional progression, for which the result was highly
significant, rather than time to distant metastases. For sur-
vival, there was a trend in favour of the combination of
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hormone treatment and chemotherapy, but differences
between the four treatments were not statistically significant.
As the ultimate aim of combining systemic treatment and
radiotherapy is to eliminate micrometastases, the results of
these trials are disappointing. Why systemic treatment should
have a marked effect on the control of locoregional disease is
uncertain. Possibly cells which metastasise have an intrin-
sically lower sensitivity to systemic treatment than cells which
remain localised. Alternatively, radiotherapy could have sen-
sitised residual loco-regional cancer cells to subsequent
systemic treatment. Mathematical modelling of the results
from the EORTC trial demonstrates that adjuvant systemic
treatment after radiotherapy might reduce the number of
residual local cancer cells by a factor of as much as 100
(Richards et al., 1988).
The substantial chemosensitivity of locally advanced breast
cancer observed in the earlier studies has led to the study of
more intensive chemotherapy for the initial treatment of
locally advanced disease. In a French study, 25 patients with
diffuse inflammatory carcinomas were treated with high dose
cyclophosphamide and 5-fluorouracil (Israel et al., 1986).
Twenty-four achieved operability and were treated by total
mastectomy after which chemotherapy was resumed and, in
the absence of recurrence, continued for 2 years. Median
disease free interval was 46 months and estimated median
survival more than 6 years; toxicity from treatment was high.
Piccart et al. (1988) treated 59 patients with locally advanced
breast cancer by combined radiotherapy, tamoxifen and
chemotherapy (doxorubicin and vincristine alternating with
CMF). All patients became operable and had total mastec-
tomy and axillary clearance after which chemotherapy was
resumed for 1 year. Treatment caused substantial toxicity;
median survival was 4 years. Hortobagyi et al. (1988) des-
cribed 126 patients with inoperable locally advanced disease
treated with a combination of 5-fluorouracil, doxorubicin
and cyclophosphamide. Response rate was 87% and, after
three cycles, patients were treated by either radiotherapy or
total mastectomy and axillary clearance followed by radio-
therapy. Thereafter chemotherapy was resumed (methotrex-
ate replacing doxorubicin) for approximately 1 year. The 5
year survival rate was 44%.
Results from these non-randomised studies suggest that
intensive primary chemotherapy may lead to a better long-
term outlook for patients presenting with locally advanced
disease. But the earlier results which raised optimism for
adjuvant systemic treatment were not confirmed in subse-
quent randomised trials and so these latest uncontrolled
studies should be viewed with caution. Given the high toxi-
city of treatment and likely selection biases, confidence in
these more aggressive approaches can only prevail once they
have been substantiated in prospective randomised controlled
trials. Only when very large differences are seen against
historical controls can we have some certainty that progress
has been made; this is not yet the case with the studies of
primary chemotherapy reported so far.
Undoubtedly, primary chemotherapy achieves a high clini-
cal response rate in locally advanced breast cancer, but
residual disease is found in the majority ofmastectomy speci-
mens (Israel et al., 1986; Piccart et al., 1988). Nevertheless,
despite this inability of chemotherapy reliably to induce
pathological complete remission, it does facilitate implemen-
tation of radical local treatment. Whether or not this in-
creases curability of locally advanced disease awaits to be
determined in randomised trials. Meanwhile, pilot studies of
potentially more effective approaches to primary chemo-
therapy need to be pursued. If higher doses of cytotoxic
drugs could be delivered to tumours safely, higher tumour
cell kill might be achieved. Intra-arterial chemotherapy has
shown some promise (Stephens, 1990), although not all
experience has been favourable (Twelves et al., 1990), and
this method of treatment is not yet established. Intensi-
fication of systemic chemotherapy with bone marrow support
by the use of haemopoietic growth factors or autologous
bone marrow transplantation could be another way forward.
In judging the effectiveness of these intensive treatments in
a disease of such high mortality it is essential to incorporate
quality of life measures into the analysis ofclinical trials. The
concept ofquality-adjusted time without symptoms ofdisease
or toxicity from treatment (Q-TWiST) has been successfully
applied to adjuvant systemic therapy for operable tumours
(Goldhirsch et al., 1991) and could well be used to enhance
the evaluation of future approaches to the treatment of
locally advanced breast cancer.
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